GO:0002353 plasma kallikrein-kinin cascade: Bradykinin Production Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002353 plasma kallikrein-kinin cascade is a blood plasma-based proteolytic cascade that generates bradykinin in response to tissue damage.
• Activated Factor XII (Hageman factor) converts prekallikrein to plasma kallikrein, which then cleaves high molecular weight kininogen to release bradykinin.
• Bradykinin is a potent vasoactive peptide that induces smooth muscle contraction, vasodilation, and increased vascular permeability.
• The cascade is implicated in angioedema, cardiovascular disease, COVID-19 severity, and inflammatory conditions.
• Key genes include F12, KLKB1, KNG1, and BDKRB1/BDKRB2, which are targets for therapeutic inhibition and CRISPR modeling.
• Research methods include knockout models, point mutations, knock-in reporters, and CRISPR library screening to dissect cascade components.
Description
The plasma kallikrein-kinin cascade (GO:0002353) is a biological process that occurs outside the cell in blood plasma, initiated by tissue damage and leading to the production of bradykinin, a potent vasoactive peptide. This cascade is a key component of the innate inflammatory response and plays a critical role in vascular biology, pain, and blood pressure regulation. Dysregulation of this cascade is associated with a range of human diseases, including hereditary angioedema, cardiovascular disorders, and severe COVID-19. Understanding the molecular players and regulatory mechanisms of this cascade is essential for developing targeted therapies. Researchers studying this pathway require robust experimental models to dissect gene function and validate therapeutic targets.
plasma kallikrein-kinin cascade At A Glance
| GO ID | GO:0002353 |
|---|---|
| GO term | plasma kallikrein-kinin cascade |
| Ontology | biological_process |
| Synonym | None |
| Major function | Generation of bradykinin from high molecular weight kininogen via plasma kallikrein, leading to vasoactive and inflammatory responses |
| Location | Extracellular, blood plasma |
| Key enzymes | Factor XII (F12), plasma kallikrein (KLKB1) |
| Key substrate | High molecular weight kininogen (KNG1) |
| End product | Bradykinin |
What Is GO:0002353?
GO:0002353 plasma kallikrein-kinin cascade is defined as a series of reactions that takes place outside the cell, occurring in response to tissue damage and initiated within blood plasma by the action of activated Factor XII (Hageman Factor) on prekallikrein to convert it to plasma kallikrein, and the subsequent reaction of plasma kallikrein with high molecular weight kininogen. The ultimate product of the plasma kallikrein-kinin cascade is bradykinin, an agent known to induce smooth muscle contraction, vasoconstriction, and increased vascular permeability.
Why Is plasma kallikrein-kinin cascade Important in Cell Biology?
The plasma kallikrein-kinin cascade is a central mediator of inflammation, vascular permeability, and pain, and its dysregulation contributes to multiple human diseases, including hereditary angioedema, cardiovascular disorders, and COVID-19 severity. Targeting this cascade has emerged as a promising therapeutic strategy, with plasma kallikrein inhibitors in clinical development for cardiovascular and inflammatory conditions. Understanding the cascade's molecular mechanisms is therefore critical for identifying new drug targets and biomarkers.
• Plasma kallikrein-kinin cascade generates bradykinin, a potent vasoactive peptide that increases vascular permeability and induces smooth muscle contraction.
• Dysregulation of the cascade leads to angioedema, a potentially life-threatening swelling disorder.
• Plasma kallikrein inhibitors are being developed for cardiovascular diseases, including thrombosis and inflammation.
• The cascade is implicated in the severity of COVID-19, with impaired kallikrein-kinin system activity observed in severe cases.
• Genetic variants in F12, KLKB1, and KNG1 are associated with altered cascade activity and disease risk.
• The cascade is a target for therapeutic intervention in inflammatory and cardiovascular disorders.
• Animal models, including teleosts, have revealed evolutionary differences in the cascade, informing comparative studies.
• Environmental factors, such as atmospheric particulate matter, can activate the cascade, linking pollution to inflammatory responses.
• CRISPR-based gene editing enables precise dissection of cascade components in cellular and animal models.
• Bioinformatics and library screening approaches accelerate the discovery of novel regulators of the cascade.
What Happens During plasma kallikrein-kinin cascade?
Initiation by Factor XII Activation
In simple terms: When tissue is damaged, a protein in the blood called Factor XII gets switched on.
The plasma kallikrein-kinin cascade is initiated when tissue damage exposes surfaces that trigger the autoactivation of Factor XII (Hageman factor) to Factor XIIa. This activation occurs in blood plasma and is a key step in the contact activation system. Factor XIIa then acts on prekallikrein, a zymogen circulating in plasma, to convert it to the active serine protease plasma kallikrein. This initial activation is critical for the subsequent amplification and progression of the cascade.
Generation of Plasma Kallikrein and Amplification
In simple terms: Factor XIIa turns prekallikrein into plasma kallikrein, which then helps make more Factor XIIa, creating a loop.
Plasma kallikrein, once generated, cleaves high molecular weight kininogen (HMWK) to release bradykinin. Additionally, plasma kallikrein can feedback to activate more Factor XII, amplifying the cascade. This positive feedback loop ensures rapid and robust bradykinin production upon tissue damage. The cascade is tightly regulated by inhibitors such as C1 inhibitor and alpha-2-macroglobulin to prevent excessive bradykinin generation.
Bradykinin Release and Receptor Activation
In simple terms: Plasma kallikrein cuts HMWK to release bradykinin, which then binds to receptors on blood vessels to cause swelling and pain.
Plasma kallikrein cleaves high molecular weight kininogen to liberate the nonapeptide bradykinin. Bradykinin then binds to G-protein-coupled receptors, primarily B2 receptor (BDKRB2), on endothelial cells, leading to vasodilation, increased vascular permeability, and smooth muscle contraction. The B1 receptor (BDKRB1) is upregulated during inflammation and contributes to sustained bradykinin effects. These receptor interactions mediate the clinical manifestations of the cascade, including edema and pain.
Downstream Signaling and Inflammatory Consequences
In simple terms: Bradykinin binding triggers signals that make blood vessels leaky and cause inflammation.
Bradykinin binding to B2 receptor activates phospholipase C, leading to increased intracellular calcium and production of nitric oxide and prostacyclin, which cause vasodilation. It also promotes phosphorylation of endothelial junction proteins, increasing vascular permeability. These effects contribute to edema formation and inflammatory cell recruitment. In pathological conditions, excessive bradykinin production due to C1 inhibitor deficiency leads to hereditary angioedema.
Regulation and Termination
In simple terms: Enzymes like ACE break down bradykinin to stop the response.
Bradykinin is rapidly degraded by angiotensin-converting enzyme (ACE), carboxypeptidase N, and other peptidases. This degradation limits the duration of bradykinin action and prevents excessive vascular leakage. C1 inhibitor is the primary regulator of Factor XIIa and plasma kallikrein, and its deficiency results in uncontrolled cascade activation. Therapeutic inhibition of plasma kallikrein is being explored to modulate the cascade in disease.
Key Genes Involved in GO:0002353 plasma kallikrein-kinin cascade
The plasma kallikrein-kinin cascade involves a network of genes encoding proteases, substrates, receptors, and regulators that collectively control bradykinin production and signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| F12 | Encodes Factor XII (Hageman factor), which initiates the cascade upon activation | Target for studying contact activation and angioedema |
| KLKB1 | Encodes plasma kallikrein, the enzyme that cleaves HMWK to release bradykinin | Therapeutic target for cardiovascular and inflammatory diseases |
| KNG1 | Encodes high molecular weight kininogen, the substrate for plasma kallikrein | Mutations linked to kininogen deficiency and disease |
| BDKRB1 | Encodes bradykinin B1 receptor, upregulated in inflammation | Target for inflammatory pain and edema |
| BDKRB2 | Encodes bradykinin B2 receptor, mediates most bradykinin effects | Target for vasodilation and permeability studies |
| SERPING1 | Encodes C1 inhibitor, the main regulator of Factor XIIa and plasma kallikrein | Deficiency causes hereditary angioedema |
| ACE | Encodes angiotensin-converting enzyme, which degrades bradykinin | ACE inhibitors increase bradykinin, causing angioedema |
| CPN1 | Encodes carboxypeptidase N, which inactivates bradykinin | Regulator of bradykinin half-life |
| F11 | Encodes Factor XI, which can be activated by Factor XIIa and contributes to coagulation | Links kallikrein-kinin system to coagulation |
| PLAT | Encodes tissue plasminogen activator, which can activate Factor XII | Connects fibrinolysis to kallikrein-kinin cascade |
| PLG | Encodes plasminogen, which can activate Factor XII and degrade kininogens | Cross-talk with fibrinolysis |
| KLK1 | Encodes tissue kallikrein, which produces lysyl-bradykinin from low molecular weight kininogen | Distinct from plasma kallikrein but related |
| BDKRB2 | B2 receptor mediates vasodilation and permeability | Drug target for angioedema |
| SERPINA1 | Encodes alpha-1 antitrypsin, which can inhibit plasma kallikrein | Modulator of cascade activity |
| AMBP | Encodes alpha-1-microglobulin/bikunin, a kininogen-related protein | Potential regulator of kinin production |
| C1QA | Encodes complement C1q, which interacts with C1 inhibitor | Link to complement system |
| C1R | Encodes complement C1r, which activates C1s | Cross-talk with complement |
| C1S | Encodes complement C1s, which cleaves C4 and C2 | Cross-talk with complement |
How Is plasma kallikrein-kinin cascade Regulated?
The plasma kallikrein-kinin cascade is regulated at multiple levels. C1 inhibitor (SERPING1) is the primary plasma inhibitor of Factor XIIa and plasma kallikrein, and its deficiency leads to uncontrolled bradykinin production and hereditary angioedema. Alpha-2-macroglobulin and antithrombin also contribute to inhibition. Bradykinin is rapidly degraded by angiotensin-converting enzyme (ACE), carboxypeptidase N, and other peptidases, limiting its duration of action. Additionally, the cascade is influenced by the contact activation system and cross-talk with the coagulation and complement systems. Therapeutic regulation via plasma kallikrein inhibitors is an active area of drug development.
plasma kallikrein-kinin cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SERPING1 | Hereditary angioedema due to C1 inhibitor deficiency | Knockout mouse model for angioedema |
| KLKB1 | Thrombosis and inflammation; target for plasma kallikrein inhibitors | KLKB1 knockout or point mutation models |
| F12 | Factor XII deficiency and angioedema | F12 knockout zebrafish or mouse |
| BDKRB2 | Vascular permeability and vasodilation | Bdkrb2 knockout mouse |
| KNG1 | Kininogen deficiency and altered bradykinin production | Kng1 knockout models |
Hereditary Angioedema
Hereditary angioedema is caused by deficiency or dysfunction of C1 inhibitor, leading to uncontrolled activation of the plasma kallikrein-kinin cascade and excessive bradykinin production. This results in recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways. Plasma kallikrein inhibitors have shown efficacy in reducing angioedema attacks.
Cardiovascular Disease
The plasma kallikrein-kinin cascade contributes to thrombosis and inflammation, and plasma kallikrein inhibitors are being developed for cardiovascular indications. Elevated bradykinin can also cause hypotension and increased vascular permeability, which may exacerbate cardiovascular events. Targeting the cascade offers a novel therapeutic approach.
COVID-19 Severity
Impaired kallikrein-kinin system activity has been observed in severe COVID-19 patients, suggesting a role in disease pathogenesis. Dysregulation of the cascade may contribute to vascular leakage and inflammation in COVID-19. Modulating the cascade could be a therapeutic strategy.
Inflammatory and Pain Disorders
Bradykinin is a potent mediator of pain and inflammation, and the cascade is implicated in inflammatory conditions such as arthritis and pancreatitis. B1 and B2 receptor antagonists are being explored for pain relief. The cascade also interacts with the complement and coagulation systems, amplifying inflammation.
From plasma kallikrein-kinin cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does KLKB1 knockout reduce bradykinin production? | KLKB1 knockout cell line or mouse |
| Can a point mutation in F12 alter cascade activation? | F12 point-mutation knock-in cell model |
| Does tagged plasma kallikrein allow real-time tracking? | KLKB1 knock-in with fluorescent tag |
| Does overexpression of BDKRB2 enhance bradykinin signaling? | BDKRB2 overexpression cell line |
| Which genes regulate the cascade in a genome-wide screen? | CRISPR library screening in endothelial cells |
| Can C1 inhibitor deficiency be modeled in vitro? | SERPING1 knockout hepatocyte cell line |
How to Study the plasma kallikrein-kinin cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Mass spectrometry | Protein and peptide levels (e.g., bradykinin) | Quantifying cascade activation in plasma |
| CRISPR knockout | Gene function loss | Dissecting KLKB1, F12, KNG1 roles |
| CRISPR knock-in | Precise mutation or tag introduction | Modeling human variants |
| Calcium flux assay | Bradykinin receptor signaling | Screening receptor antagonists |
| ELISA | Bradykinin or kallikrein concentration | Clinical biomarker measurement |
| CRISPR library screening | Genome-wide gene function | Identifying novel cascade regulators |
| RNA-seq | Transcriptional changes | Pathway analysis after cascade activation |
| Western blot | Protein expression and cleavage | Validating knockout or overexpression |
Proteomic and Peptidomic Analysis
Mass spectrometry-based proteomics and peptidomics can quantify plasma kallikrein, Factor XIIa, and bradykinin levels in biological samples. These methods enable monitoring of cascade activation in disease models and clinical samples. Targeted assays can detect post-translational modifications and cleavage products.
Genetic Knockout and Knock-in Models
CRISPR-Cas9-mediated knockout of KLKB1, F12, or KNG1 in cell lines and animal models allows functional dissection of the cascade. Knock-in of point mutations or tags enables precise modeling of human variants. These models are essential for validating drug targets.
Reporter Assays for Bradykinin Signaling
Bradykinin-induced calcium flux and nitric oxide production can be measured using fluorescent reporters in endothelial cells. Receptor activation assays using BDKRB1/BDKRB2 overexpression systems help quantify signaling. These assays are used for high-throughput screening of inhibitors.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens can identify novel regulators of the plasma kallikrein-kinin cascade. Such screens have been used to discover genes affecting bradykinin production and vascular permeability. Bioinformatics analysis of screening data reveals pathway enrichment and candidate targets.
How CRISPR Can Be Used to Study GO:0002353 plasma kallikrein-kinin cascade
Knockout
CRISPR knockout of KLKB1, F12, or KNG1 in cell lines or animal models abolishes specific cascade components, allowing researchers to determine their necessity for bradykinin production. For example, KLKB1 knockout endothelial cells show reduced bradykinin release upon stimulation. These models are valuable for target validation in drug discovery.
Point Mutation
Introducing disease-associated point mutations (e.g., in F12 or SERPING1) via CRISPR base editing or homology-directed repair enables modeling of human genetic variants. Such models help elucidate how specific mutations alter cascade activity and disease risk. They are also useful for testing personalized therapeutics.
Knock-in
Knock-in of fluorescent or epitope tags into KLKB1 or KNG1 allows real-time tracking of protein localization and secretion. Tagged knock-in models facilitate live-cell imaging and biochemical purification. They are instrumental in studying cascade dynamics in response to tissue damage.
Overexpression
Overexpression of BDKRB2 or KLKB1 in cell lines amplifies bradykinin signaling or production, enabling sensitive assays for inhibitor screening. Overexpression models can also reveal gain-of-function phenotypes relevant to disease. These systems are complementary to knockout approaches.
How EDITGENE Supports plasma kallikrein-kinin cascade Research
Researchers studying plasma kallikrein-kinin cascade-related genes often need to determine whether a candidate gene is causally involved in bradykinin production, vascular permeability, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for plasma kallikrein-kinin cascade research.
Frequently Asked Questions About plasma kallikrein-kinin cascade
What is the plasma kallikrein-kinin cascade?
The plasma kallikrein-kinin cascade (GO:0002353) is a series of extracellular reactions in blood plasma that generates bradykinin in response to tissue damage, initiated by Factor XII activation of prekallikrein.
What genes are involved in the plasma kallikrein-kinin cascade?
Key genes include F12, KLKB1, KNG1, BDKRB1, BDKRB2, and SERPING1, which encode the protease, substrate, receptors, and regulator of the cascade.
What is the role of plasma kallikrein?
Plasma kallikrein is a serine protease that cleaves high molecular weight kininogen to release bradykinin, a potent vasoactive peptide.
How is the plasma kallikrein-kinin cascade regulated?
It is regulated by C1 inhibitor, alpha-2-macroglobulin, and peptidases such as ACE that degrade bradykinin.
What diseases are associated with the plasma kallikrein-kinin cascade?
Diseases include hereditary angioedema, cardiovascular disorders, COVID-19 severity, and inflammatory pain conditions.
What is bradykinin and what does it do?
Bradykinin is a nonapeptide that induces smooth muscle contraction, vasodilation, and increased vascular permeability, contributing to inflammation and edema.
How can I study the plasma kallikrein-kinin cascade in the lab?
Common methods include CRISPR knockout of KLKB1 or F12, bradykinin ELISA, calcium flux assays, and proteomics.
What are plasma kallikrein inhibitors?
Plasma kallikrein inhibitors are therapeutic agents that block kallikrein activity, reducing bradykinin production, and are in development for cardiovascular and inflammatory diseases.
Is the plasma kallikrein-kinin cascade present in all animals?
The cascade is conserved in mammals but appears to be lacking in teleost fish, indicating evolutionary divergence.
How does COVID-19 affect the kallikrein-kinin system?
Severe COVID-19 is associated with impaired kallikrein-kinin system activity, which may contribute to vascular leakage and inflammation.
Conclusion
The plasma kallikrein-kinin cascade (GO:0002353) is a fundamental extracellular proteolytic pathway that generates bradykinin, a key mediator of inflammation, vascular permeability, and pain. Its dysregulation underlies hereditary angioedema, cardiovascular disease, and COVID-19 severity, making it a prime therapeutic target. Advances in CRISPR gene editing and screening technologies are accelerating the discovery of novel cascade regulators and drug candidates. EDITGENE's comprehensive services support researchers in dissecting this cascade with precision and scale.
References
- 1. Zhang Y et al.. 2023. Tracing the plasma kallikrein-kinin system-activating component in the atmospheric particulate matter with different origins.. J Hazard Mater 458:132044 PMID: 37451104
- 2. Björkqvist J et al.. 2013. Plasma kallikrein: the bradykinin-producing enzyme.. Thromb Haemost 110(3):399-407 PMID: 23846131
- 3. Kolte D et al.. 2016. Plasma Kallikrein Inhibitors in Cardiovascular Disease: An Innovative Therapeutic Approach.. Cardiol Rev 24(3):99-109 PMID: 25853524
- 4. Wisniewski P et al.. 2024. Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system.. J Transl Med 22(1):388 PMID: 38671481
- 5. Wong MK et al.. 2013. Lack of plasma kallikrein-kinin system cascade in teleosts.. PLoS One 8(11):e81057 PMID: 24278376
- 6. Alfaro E et al.. 2022. Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity.. Front Immunol 13:909342 PMID: 35812405
- 7. Kaplan AP. 2008. Angioedema.. World Allergy Organ J 1(6):103-13 PMID: 23282406
- 8. Moreau ME et al.. 2005. The kallikrein-kinin system: current and future pharmacological targets.. J Pharmacol Sci 99(1):6-38 PMID: 16177542
